Maravai Lifesciences Company Top Insiders
MRVI Stock | USD 2.30 0.06 2.68% |
Under 67% of Maravai Lifesciences' corporate insiders are selling. The analysis of insiders' sentiment of trading Maravai Lifesciences Holdings stock suggests that many insiders are alarmed at this time. Maravai Lifesciences employs about 570 people. The company is managed by 17 executives with a total tenure of roughly 1330 years, averaging almost 78.0 years of service per executive, having 33.53 employees per reported executive.
Insider Sentiment 33
Mostly Selling
Selling | Buying |
Latest Trades
2025-01-31 | Kurt Oreshack | Disposed 25000 @ 5.03 | View | ||
2024-11-11 | Carl Hull | Acquired 175000 @ 5.64 | View | ||
2024-05-28 | Gtcr Investment Xi Llc | Disposed 9940974 @ 9.81 | View |
Monitoring Maravai Lifesciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Maravai |
Maravai Lifesciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3798) %, meaning that it created substantial loss on money invested by shareholders. Maravai Lifesciences' management efficiency ratios could be used to measure how well Maravai Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.21. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.24. As of now, Maravai Lifesciences' Non Currrent Assets Other are increasing as compared to previous years. The Maravai Lifesciences' current Other Assets is estimated to increase to about 973.4 M, while Other Current Assets are projected to decrease to under 15.4 M.The Maravai Lifesciences' current Common Stock Shares Outstanding is estimated to increase to about 167.4 M. The Maravai Lifesciences' current Net Income Applicable To Common Shares is estimated to increase to about 265.9 M
Maravai Lifesciences Workforce Comparison
Maravai Lifesciences Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 16,990. Maravai Lifesciences holds roughly 570 in number of employees claiming about 3% of equities under Health Care industry.
Maravai Lifesciences Profit Margins
The company has Profit Margin (PM) of (0.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.67 | 0.4179 |
|
|
Maravai Lifesciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Maravai Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Maravai Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Maravai Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.375 | 6 | 16 | 2,613,415 | 459,115 |
2024-12-01 | 2.6667 | 8 | 3 | 353,515 | 75,851 |
2024-06-01 | 4.0 | 16 | 4 | 8,625,295 | 26,777,624 |
2024-03-01 | 0.8 | 8 | 10 | 2,275,247 | 64,854 |
2023-12-01 | 1.5 | 3 | 2 | 4,039 | 70,746 |
2023-09-01 | 11.0 | 11 | 1 | 547,901 | 5,578 |
2023-03-01 | 1.1111 | 10 | 9 | 1,129,422 | 4,754,486 |
2022-03-01 | 3.3333 | 10 | 3 | 434,000 | 13,300 |
2021-12-01 | 7.0 | 14 | 2 | 44,445 | 5,140,830 |
2021-06-01 | 0.6667 | 4 | 6 | 2,194 | 38,365,959 |
2020-12-01 | 7.0 | 21 | 3 | 645,500 | 64,823,011 |
Maravai Lifesciences Notable Stakeholders
A Maravai Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Maravai Lifesciences often face trade-offs trying to please all of them. Maravai Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Maravai Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Carl Hull | CoFounder Chairman | Profile | |
Robert MBA | Chairman Board | Profile | |
Andrew Burch | President Production | Profile | |
Kevin Herde | Executive CFO | Profile | |
Kevin CPA | Executive CFO | Profile | |
Kurt Oreshack | General VP | Profile | |
Kurt JD | General VP | Profile | |
Christine Dolan | Executive Technologies | Profile | |
Brian Neel | Chief Production | Profile | |
Peter Leddy | Executive Officer | Profile | |
Christopher Benoit | Executive Enzymes | Profile | |
Becky Buzzeo | Executive Officer | Profile | |
Kate Broderick | Executive Officer | Profile | |
Rebecca Buzzeo | Executive Officer | Profile | |
Debra Hart | Director Relations | Profile | |
Doreen Pippen | VP Marketing | Profile | |
William III | Chief Officer | Profile |
About Maravai Lifesciences Management Performance
The success or failure of an entity such as Maravai Lifesciences often depends on how effective the management is. Maravai Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Maravai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Maravai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.22) | (0.21) | |
Return On Capital Employed | (0.25) | (0.24) | |
Return On Assets | (0.14) | (0.14) | |
Return On Equity | (0.45) | (0.42) |
Maravai Lifesciences Workforce Analysis
Traditionally, organizations such as Maravai Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Maravai Lifesciences within its industry.Maravai Lifesciences Manpower Efficiency
Return on Maravai Lifesciences Manpower
Revenue Per Employee | 454.7K | |
Revenue Per Executive | 15.2M | |
Net Loss Per Employee | 455.5K | |
Net Loss Per Executive | 15.3M | |
Working Capital Per Employee | 652.9K | |
Working Capital Per Executive | 21.9M |
Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |